Epidemiology of Endophthalmitis and Treatment Trend in Europe

Grzybowski, Andrzej; Turczynowska, Magdalena

doi:10.1007/978-981-10-5260-6_5

Cited by 1 publication

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… ● The choice of the target drug and treatment strategy should be made according to the characteristics and needs of each patient since the selected treatment involves a certain frequency of intravitreal injections and regular monitoring visits that can have a negative impact on the quality of life and/or lifestyle of the patient.Treatment administration should follow accepted procedures to avoid the risk of endophthalmitis. 47 , 48 These include the use of topical antiseptic to irrigate the ocular surface and conjunctival sac prior to intravitreal injection procedure in a clean room. The preferred antiseptic is povidone-iodine 5%, with chlorhexidine 0.1% aqueous solution as an alternative in patients that report an allergy to iodine.…”

Section: Resultsmentioning

confidence: 99%

“…Treatment administration should follow accepted procedures to avoid the risk of endophthalmitis. 47,48 These include the use of topical antiseptic to irrigate the ocular surface and conjunctival sac prior to intravitreal injection procedure in a clean room. The preferred antiseptic is povidone-iodine 5%, with chlorhexidine 0.1% aqueous solution as an alternative in patients that report an allergy to iodine.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Expert Panel Consensus for Addressing Anti-VEGF Treatment Challenges of Diabetic Macular Edema in Spain

Fernández‐Vigo¹,

Contreras²,

Crespo³

et al. 2022

OPTH

View full text Add to dashboard Cite

Purpose The treatment of diabetic macular edema (DME) has evolved rapidly in the past decade, highlighting the need to address the challenges of routine clinical practice decision-making through expert consensus agreements. Methods After a literature review and discussion of real-world experience on DME management, a group of ten retina specialists agreed on a consensus of recommendations for the most appropriate management of DME patients using vascular endothelial growth factor inhibitors (anti-VEGF) in Spain. Results The panel recommended early treatment initiation in DME patients with worse baseline visual acuity (VA) to maintain or improve outcome. For patients with good VA, an observation strategy was recommended, considering the presence of diabetic retinopathy, optical coherence tomography biomarkers, and impact on patient’s quality of life. Based on the available evidence and clinical experience, the panel recommended the use of anti-VEGF intensive loading doses with the objective of achieving anatomic and visual responses as soon as possible, followed by a Treat & Extend (T&E) strategy to maintain VA improvement. Aflibercept was recommended for patients with a baseline decimal VA <0.5, followed by a T&E strategy, including the possibility to extend frequency of injections up to 16 weeks. Conclusion An expert panel proposes a consensus for the management of DME in Spain. Early treatment initiation with anti-VEGF in DME patients is recommended to maintain or improve VA; aflibercept is recommended for patients with a poor baseline VA.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%